• Introduced
    Feb 07, 2022
  • Passed House
    Mar 07, 2022
  • Passed Senate
  • Became Law
HB 3414
Oklahoma House Bill
Did you know we offer free bill tracking in Congress and 50 states, AI tools to streamline your work, and a great mobile app? Sign up here
Controlled dangerous substances; authorizing certain research and clinical trials related to psilocybin and psilocin; requiring registration; providing certain immunities.
Last Action See all actions
Senate • Apr 14, 2022: Coauthored by Representative Pae
Latest Bill Text See all bill texts

Summary

Comments on HB 3414

Tweets

Whip Lists

Sponsors
Votes
Actions
  • Apr 14, 2022 | Senate
    • remove as coauthor Representative(s) Phillips
    • remove as principal author Representative Pae and substitute with Representative Phillips
    • Coauthored by Representative Pae
  • Apr 11, 2022 | Senate
    • Reported Do Pass, amended by committee substitute Health and Human Services committee; CR filed
    • Title stricken
  • Mar 24, 2022 | Senate
    • Second Reading referred to Health and Human Services
  • Mar 08, 2022 | Senate
    • First Reading
  • Mar 08, 2022 | House
    • Engrossed, signed, to Senate
  • Mar 07, 2022 | House
    • General Order
    • Coauthored by Representative(s) Manger, Walke, Brewer, Munson
    • House Rule suspended
    • Amended by floor substitute
    • Third Reading, Measure passed and Emergency failed: Ayes: 62 Nays: 30; Ayes: 66 Nays: 25
    • Referred for engrossment
  • Feb 16, 2022 | House
    • CR; Do Pass, amended by committee substitute Public Health Committee
    • Coauthored by Representative(s) Phillips, Rosecrants, McEntire, Martinez, Dempsey, Dollens, Humphrey, Echols, Talley, McDugle, Davis
    • Authored by Senator Paxton (principal Senate author)
  • Feb 08, 2022 | House
    • Second Reading referred to Public Health
  • Feb 07, 2022 | House
    • First Reading
    • Authored by Representative Pae